Global spending on medicines will reach $1.4 trillion in 2020, driven by increased healthcare access in emerging markets and high-priced new drugs for cancer and other diseases, according to a forecast by IMS Health released on Wednesday. That is up from about $1.07 trillion this year, representing a compound annual growth rate of 4 to 7 percent over the next five years, the "Global Medicines Use in 2020" report compiled by IMS Institute for Healthcare Informatics found. Some 225 new drugs will
NAI500 Comments: i. The Chinese government is heavily focused on the health of its citizens as shown by its decision to build 7,500 public hospitals through the private sector over the next decade. ii. China’s health challenges include significantly high rates of smoking, high pollution levels, and a rapidly aging population. iii. Given China’s healthcare challenges, Canadian healthcare developers should target cancer treatment, heart disease treatment, and age related solutions. iv. The cit
South Korean biotech Genexine Inc. licensed out three of its compounds for $100 million to a Chinese drug developer, exploring the Asian market for next-generation long-acting growth hormone treatments. Clinical-stage Genexine (KOSDAQ:095700) signed a licensing and technology transfer agreement with China's Tasgen, a subsidiary of Tasly Pharmaceutical Group Co. Ltd. (SH:600535). Under the deal reached this week, Genexine will grant the China rights for three compounds, GX-H9, GX-G6 and GX-G3, to Tasgen i
China has updated list of medicines covered by basic medical insurance schemes, a long-awaited fillip for drugmakers in the world's second-largest drug market where many new drugs hav...
CohBar is an innovator and leader in the research and development of mitochondria-based therapeut...
Race Capital Corp is a Capital Pool Company. The principal business of the Company is the identif...
Replicel Life Sciences Inc is a clinical stage bio-pharmaceutical company engaged in developing a...
Gilber Chan, the President of NAI500, presents the latest speech of 2016 investment strategy on Global Chinese Financial Forum - Vancouver Conference 2016: The Top 10 Developments...
China's policymakers still have ammunition to counter the mainland's slowing economy, including supply-side reforms and subsidized housing, HSBC said. In a note released Tu...
Consumer staples and services, health care, software and auto stocks are Henderson Global Investors' top Chinese stock picks for 2016 — but don't get your hopes up for a...
The leaders of the world's largest economies stuck to a goal of lifting their collective output by an extra 2 percent by 2018, even though growth remains uneven and weaker than expect...
The renminbi's status as a global reserve currency may be effectively guaranteed following formal backing by International Monetary Fund (IMF) staff, according to economists, but trad...
, a clinical stage regenerative medicine company focused on the development of autologous cell therapies, is pleased to announce that it has completed its financing announced on February ...
today announced the receipt of the final minutes of an in-person Type B meeting with the Cardiovascular and Renal Products Division of the U.S. Food and Drug Administration (FDA). The pur...
, a preclinical stage biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that it has completed a study to ev...
|Company Name||Symbol||Price||Change||Vol(k)||Day's Range||Contact|
|1||IntelliPharmaCeutics International Inc||NASDAQ:IPCI||2.550||
||5525503||2.50 - 2.82|
||900869||0.29 - 0.35|
|3||Aurinia Pharmaceuticals Inc||TSX:AUP||4.880||
||129017||4.29 - 4.90|
||172830||4.90 - 5.25|
|5||Alphatec Holdings Inc||NASDAQ:ATEC||3.550||
||97699||3.25 - 3.65|
|6||Galectin Therapeutics Inc||NASDAQ:GALT||1.900||
||366007||1.72 - 1.90|
|7||TG Therapeutics Inc||NASDAQ:TGTX||5.900||
||657601||5.50 - 6.00|
|8||Ocera Therapeutics Inc||NASDAQ:OCRX||0.629||
||673220||0.5812 - 0.6285|
||232198||0.4551 - 0.5390|
|10||Retractable Technologies Inc||NYSE MKT:RVP||1.070||
||48159||1.01 - 1.07|
|11||RTI Surgical Inc||NASDAQ:RTIX||3.600||
||180816||3.45 - 3.70|
|12||Conatus Pharmaceuticals Inc||NASDAQ:CNAT||4.950||
||130754||4.75 - 4.96|
|13||Trimel Pharmaceuticals Corp||TSX:TRL||9.750||
||200||9.75 - 9.83|
|14||Alimera Sciences Inc||NASDAQ:ALIM||1.260||
||540917||1.16 - 1.26|
|15||Sunesis Pharmaceuticals Inc||NASDAQ:SNSS||4.290||
||62655||4.11 - 4.33|